-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] At present, Fosun Pharma's CAR-T cell therapy product Yikaida (Aquilence Injection) has been put into clinical use
.
It is reported that as of the end of February 2022, the product has been included in urban Huimin Insurance and more than 40 commercial insurances in 23 provinces and cities across the country.
The number of registered treatment centers has reached 75, and about 100 patients have entered the treatment process
.
In June 2021, ikaida was approved to become the first CART cell therapy product approved for marketing in China, which is mainly used for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after receiving second-line or above systemic therapy
.
In August 2021, the second indication of Ikeda (for the treatment of adult patients with relapsed or refractory indolent non-Hodgkin lymphoma including follicular lymphoma and marginal zone lymphoma) was approved by the State Food and Drug Administration Included in the Breakthrough Therapy Drug Program
.
In addition, Fosun Pharma stated that the technology transfer of the second CAR-T product has been completed within the reporting period, and the clinical trial application for relapsed or refractory mantle cell lymphoma was approved for clinical trials by the State Food and Drug Administration in March 2022.
approved
.
It is worth mentioning that the price of CAR-T cell therapy products has always been expensive
.
Previously, a drug sales order for Achilles injection showed that the retail price of the product was 1.
2 million yuan per injection, and it did not include outpatient and inpatient treatment costs
.
After all, this is an unbearable cost for the majority of patients' families.
When Yikaida can enter the medical insurance has also attracted the attention of patients
.
On March 23, Wu Yifang, Chairman and CEO of Fosun Pharma, revealed at the performance communication meeting that the current reimbursement rate of CAR-T cell therapy Huimin Insurance is relatively low.
to more health insurance support
.
This also means that Yikaida is likely to actively strive for medical insurance in the future, which will benefit the majority of lymphoma patients
.
Lymphoma is a malignant tumor that seriously threatens the health of the Chinese population
.
According to the different pathology, lymphoma can be divided into Hodgkin lymphoma and non-Hodgkin lymphoma
.
In China, the proportion of non-Hodgkin lymphoma in malignant lymphoma is much higher than that of Hodgkin lymphoma, and the disease can occur in people of any age
.
Non-Hodgkin's lymphoma is a malignant tumor originating from the lymphatic system, which is manifested by the uncontrolled proliferation of abnormal lymphoma cells in lymphoid organs (lymph nodes, spleen, etc.
) or non-lymphoid organs, resulting in enlarged lymph nodes, destruction of organ structure, and compression.
, Obstruction of adjacent organs, and accompanied by systemic symptoms
.
At present, the total number of patients with lymphoma in China is as high as nearly 90,000, with an incidence rate of 6.
44/100,000, and is increasing year by year
.
"Healthy China Action (2019-2030)" proposes that by 2030, the overall 5-year cancer survival rate will increase by 15%
.
However, at present, lymphoma patients in China still face the pain points of high misdiagnosis rate and low cure rate
.
The industry pointed out that in the past, the domestic treatment for lymphoma mainly relied on chemotherapy.
With the development of new medical technology, now immune or targeted therapy has become a new means of lymphoma treatment
.
As a new type of precise targeted therapy for the treatment of tumors, CAR-T cell therapy can achieve precise, rapid and efficient therapeutic effects.
The birth of CAR-T cell immunotherapy has also brought hope to the majority of tumor patients.
If Yikaida can succeed in the future Entering medical insurance will bring good news to tens of thousands of patients in China, reduce the cost burden, and improve the quality of life of patients
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is reported that as of the end of February 2022, the product has been included in urban Huimin Insurance and more than 40 commercial insurances in 23 provinces and cities across the country.
The number of registered treatment centers has reached 75, and about 100 patients have entered the treatment process
.
In June 2021, ikaida was approved to become the first CART cell therapy product approved for marketing in China, which is mainly used for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after receiving second-line or above systemic therapy
.
In August 2021, the second indication of Ikeda (for the treatment of adult patients with relapsed or refractory indolent non-Hodgkin lymphoma including follicular lymphoma and marginal zone lymphoma) was approved by the State Food and Drug Administration Included in the Breakthrough Therapy Drug Program
.
In addition, Fosun Pharma stated that the technology transfer of the second CAR-T product has been completed within the reporting period, and the clinical trial application for relapsed or refractory mantle cell lymphoma was approved for clinical trials by the State Food and Drug Administration in March 2022.
approved
.
It is worth mentioning that the price of CAR-T cell therapy products has always been expensive
.
Previously, a drug sales order for Achilles injection showed that the retail price of the product was 1.
2 million yuan per injection, and it did not include outpatient and inpatient treatment costs
.
After all, this is an unbearable cost for the majority of patients' families.
When Yikaida can enter the medical insurance has also attracted the attention of patients
.
On March 23, Wu Yifang, Chairman and CEO of Fosun Pharma, revealed at the performance communication meeting that the current reimbursement rate of CAR-T cell therapy Huimin Insurance is relatively low.
to more health insurance support
.
This also means that Yikaida is likely to actively strive for medical insurance in the future, which will benefit the majority of lymphoma patients
.
Lymphoma is a malignant tumor that seriously threatens the health of the Chinese population
.
According to the different pathology, lymphoma can be divided into Hodgkin lymphoma and non-Hodgkin lymphoma
.
In China, the proportion of non-Hodgkin lymphoma in malignant lymphoma is much higher than that of Hodgkin lymphoma, and the disease can occur in people of any age
.
Non-Hodgkin's lymphoma is a malignant tumor originating from the lymphatic system, which is manifested by the uncontrolled proliferation of abnormal lymphoma cells in lymphoid organs (lymph nodes, spleen, etc.
) or non-lymphoid organs, resulting in enlarged lymph nodes, destruction of organ structure, and compression.
, Obstruction of adjacent organs, and accompanied by systemic symptoms
.
At present, the total number of patients with lymphoma in China is as high as nearly 90,000, with an incidence rate of 6.
44/100,000, and is increasing year by year
.
"Healthy China Action (2019-2030)" proposes that by 2030, the overall 5-year cancer survival rate will increase by 15%
.
However, at present, lymphoma patients in China still face the pain points of high misdiagnosis rate and low cure rate
.
The industry pointed out that in the past, the domestic treatment for lymphoma mainly relied on chemotherapy.
With the development of new medical technology, now immune or targeted therapy has become a new means of lymphoma treatment
.
As a new type of precise targeted therapy for the treatment of tumors, CAR-T cell therapy can achieve precise, rapid and efficient therapeutic effects.
The birth of CAR-T cell immunotherapy has also brought hope to the majority of tumor patients.
If Yikaida can succeed in the future Entering medical insurance will bring good news to tens of thousands of patients in China, reduce the cost burden, and improve the quality of life of patients
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
